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1. Introduction  
Chronic pain has been recognized as pain that persists past normal healing time [5] and hence 
lacks the acute warning function of physiological nociception [35]. Usually pain is regarded 
as chronic when it lasts or recurs for more than 3-6 months [29]. Chronic pain is a frequent 
condition, affecting an estimated 20% of people worldwide [6,9,14,15] and accounting for 15-
20% of physician visits [25,28]. Chronic pain should receive greater attention as a global 
health priority, since adequate pain treatment is a human right, and it is the duty of any health-
care system to provide it [4,14]. 
The current version of the International Classification of Diseases (ICD) of the World Health 
Organisation (WHO) includes some diagnostic codes for chronic pain conditions, but these 
diagnoses do not reflect the actual epidemiology of chronic pain, nor are they categorized in a 
systematic manner. The ICD is the preeminent tool for coding diagnoses and documenting 
investigations or therapeutic measures within the healthcare systems of many countries. In 
addition, ICD codes are commonly used to report target diseases and comorbidities of 
participants in clinical research. Consequently, the current lack of adequate coding in the ICD 
makes the acquisition of accurate epidemiological data related to chronic pain difficult, 
prevents adequate billing for healthcare expenses related to pain treatment, and hinders the 
development and implementation of new therapies [11,12,17,23,27,31,37]. 
Responding to these shortcomings, the International Association for the Study of Pain (IASP) 
contacted the WHO and established a Task Force for the Classification of Chronic Pain. The 
IASP Task Force, which comprises pain experts from across the globe [19], has developed a 
new and pragmatic classification of chronic pain for the upcoming 11th revision of the ICD. 
The goal is to create a classification system that is applicable in primary care as well as in 
clinical settings for specialized pain management.  
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A major challenge in this process was finding a rational principle of classification that suits 
the different types of chronic pain and fits into the general ICD-11 framework. Pain categories 
are variably defined based on perceived location (headache), etiology (cancer pain) or the 
primarily affected anatomical system (neuropathic pain). Some diagnoses of pain defy these 
classification principles (fibromyalgia).  
This problem is not unique to the classification of pain, but exists throughout the ICD. The 
IASP Task Force decided to give first priority to pain etiology, followed by underlying 
pathophysiological mechanisms, and finally body site. Developing this multilayered 
classification was greatly facilitated by a novel principle of assigning diagnostic codes in 
ICD-11, termed “multiple parenting”. Multiple parenting allows the same diagnosis to be 
subsumed under more than one category. Each diagnosis retains one category as primary 
parent, but is cross-referenced to other categories that function as secondary parents.  
 
The new ICD category for “Chronic Pain” comprises the most common clinically relevant 
disorders. These disorders were divided into seven groups (Fig. 1): (i) chronic primary pain; 
(ii) chronic cancer pain; (iii) chronic posttraumatic and postsurgical pain; (iv) chronic 
neuropathic pain; (v) chronic headache and orofacial pain; (vi) chronic visceral pain; (vii) 
chronic musculoskeletal pain. Experts assigned to each group are responsible for the 
definition of diagnostic criteria and the selection of the diagnoses to be included under these 
subcategories of chronic pain. Thanks to Bedirhan Üstün and Robert Jakob of the WHO, these 
pain diagnoses are now integrated in the beta version of ICD-11 
(http://id.who.int/icd/entity/1581976053). The Task Force is generating content models for 
single entities to describe their clinical characteristics. Following peer review overseen by the 
WHO Steering Committee, the classification of chronic pain will be voted into action by the 
World Health Assembly in 2017. 
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2. Classification of chronic pain 
Chronic pain was defined as persistent or recurrent pain lasting longer than 3 months. This 
definition according to pain duration has the advantage that it is clear and operationalized. It 
includes the vast majority of relevant conditions. Conditions in which an earlier diagnosis of 
chronic pain is justified will be included with their own set of criteria. 
Optional specifiers for each diagnosis record evidence of psychosocial factors and the severity 
of the pain. Pain severity can be graded based on pain intensity, pain-related distress and 
functional impairment. 
 
2.1 Chronic primary pain  
Chronic primary pain is pain in one or more anatomic regions that persists or recurs for longer 
than 3 months and is associated with emotional distress or functional disability (interference 
with activities of daily life and participation in social roles) and that cannot be better 
explained by another chronic pain condition. This is a new phenomenological definition, 
created because for many forms of chronic pain the etiology is unknown. Common conditions 
such as e.g. back pain that is neither identified as musculoskeletal or neuropathic pain, chronic 
widespread pain, fibromyalgia and irritable bowel syndrome will be found in this section. The 
term “primary pain” was chosen in close liaison with the ICD-11 revision committee, who felt 
this was the most widely acceptable term, in particular from a non-specialist perspective.  
 
2.2. Chronic cancer pain  
Pain is a frequent and debilitating accompaniment of cancer [8] that as yet has not been 
represented in the ICD. The Task Force decided to list it as a separate entity because there are 
specific treatment guidelines [7,38]. Chronic cancer pain includes pain caused by the cancer 
itself (the primary tumor or metastases) and pain that is caused by the cancer treatment 
(surgical, chemotherapy, radiotherapy, other). Cancer-related pain will be subdivided based 
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on location into visceral, bony (or musculoskeletal) and somatosensory (neuropathic), and 
will be described as either continuous (background pain) or intermittent (episodic pain) if 
associated with physical movement or clinical procedures. The treatment-related pain will be 
cross-referenced from the chapters on postsurgical pain and neuropathic pain.  
 
2.3 Chronic postsurgical and posttraumatic pain 
Since pain that persists beyond normal healing is frequent after surgery and some types of 
injuries, the entity of postsurgical and posttraumatic pain was created. This is defined as pain 
that develops after a surgical procedure or a tissue injury (involving any trauma including 
burns) and persists at least 3 months after surgery or tissue trauma [26]; this is a definition of 
exclusion, as all other causes of pain (infection, recurring malignancy) as well as pain from a 
pre-existing pain problem need to be excluded. In view of the different causality, as well as 
from a medicolegal point of view, a separation between postsurgical pain and pain after all 
other trauma is regarded as useful. Depending on the type of surgery, chronic postsurgical 
pain often is neuropathic pain (on average 30% of cases with a range from 6 to 54% and 
more) [16]. Pain including such a neuropathic component is usually more severe than 
nociceptive pain and often affects the quality of life more adversely [21]. 
 
2.4 Chronic neuropathic pain  
Chronic neuropathic pain is caused by a lesion or disease of the somatosensory nervous 
system [20,22]. The somatosensory nervous system provides information about the body 
including skin, musculoskeletal and visceral organs. Neuropathic pain may be spontaneous or 
evoked, as an increased response to a painful stimulus (hyperalgesia) or a painful response to 
a normally nonpainful stimulus (allodynia). The diagnosis of neuropathic pain requires a 
history of nervous system injury, for example, by a stroke, nerve trauma or diabetic 
neuropathy, and a neuroanatomically plausible distribution of the pain [22]. For the 
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identification of definite neuropathic pain, it is necessary to demonstrate the lesion or disease 
involving the nervous system, for example, by imaging, biopsy, neurophysiological or 
laboratory tests. In addition, negative or positive sensory signs compatible with the 
innervation territory of the lesioned nervous structure must be present [36]. Diagnostic entities 
within this category will be divided into conditions of peripheral or central neuropathic pain. 
 
2.5 Chronic headache and orofacial pain  
The International Headache Society (IHS) has created a headache classification [18] that is 
implemented in full in the chapter on neurology. This classification differentiates between 
primary (idiopathic), secondary (symptomatic) headache and orofacial pain including cranial 
neuralgias. In the section on chronic pain, only chronic headache and chronic orofacial pain 
will be included. Chronic headache and orofacial pain is defined as headaches or orofacial 
pains that occur on at least 50% of the days during at least 3 months. For most purposes, 
patients receive a diagnosis according to the headache phenotypes or orofacial pains that they 
currently present. The section will list the most frequent chronic headache conditions.  
The most common chronic orofacial pains are temporomandibular disorders [32], which have 
been included in this subchapter of chronic pain. Chronic orofacial pain can be a localized 
presentation of a primary headache [2]. This is common in the trigeminal autonomic 
cephalalgias, less common in migraines and rare in tension-type headache. Several chronic 
orofacial pains such as post-traumatic trigeminal neuropathic pain [3], persistent idiopathic 
orofacial pain, and burning mouth syndrome are cross-referenced to e.g. primary chronic pain 
and neuropathic pain. The temporal definition of ‘chronic’ has been extrapolated from that of 
chronic headaches [1].  
 
2.6 Chronic visceral pain  
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Chronic visceral pain is persistent or recurrent pain that originates from the internal organs of 
the head/neck region and the thoracic, abdominal and pelvic cavities [24,33,34]. The pain is 
usually perceived in the somatic tissues of the body wall (skin, subcutis, muscle) in areas that 
receive the same sensory innervation as the internal organ at the origin of the symptom 
(referred visceral pain) [13]. In these areas, secondary hyperalgesia (increased sensitivity to 
painful stimuli in areas other than the primary site of the nociceptive input) often occurs [30]; 
the intensity of the symptom may bear no relationship with the extent of the internal 
damage/noxious visceral stimulation [10]. The section on visceral pain will be subdivided 
according to the major underlying mechanisms, i.e. persistent inflammation, vascular 
mechanisms (ischemia, thrombosis), obstruction/distension, traction/compression, combined 
mechanisms (e.g., obstruction and inflammation concurrently), and referral from other 
locations. Pain due to cancer will be cross-referenced to the chapter chronic cancer pain and 
pain due to functional or unexplained mechanisms to chronic primary pain. 
 
2.7 Chronic musculoskeletal pain  
Chronic musculoskeletal pain is defined as persistent or recurrent pain that arises as part of a 
disease process directly affecting bone(s), joint(s), muscle(s) or related soft tissue(s). 
According to the constraints of the approach as described in the Introduction, this category is 
therefore limited to nociceptive pain and does not include pain that may be perceived in 
musculoskeletal tissues but does not arise therefrom, such as the pain of compression 
neuropathy or somatic referred pain. The entities subsumed in this approach include those 
characterized by persistent inflammation of infectious, auto-immune or metabolic etiology, 
such as rheumatoid arthritis, and by structural changes affecting bones, joints, tendons or 
muscles, such as symptomatic osteoarthrosis. Musculoskeletal pain of neuropathic origin will 
be cross-referenced to neuropathic pain. Well-described apparent musculoskeletal conditions 
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for which the causes are incompletely understood, such as non-specific back pain or chronic 
widespread pain, will be included in the section on chronic primary pain.  
 
3. Outlook 
Irrespective of its etiology, chronic pain is a major source of suffering and requires special 
treatment and care. Our proposal may not represent a perfect solution for the classification of 
all manifestations of chronic pain. However, it does represent the first systematic approach to 
implementing a classification of chronic pain in the ICD. It is based on international expertise 
and agreement, and consistent with the requirements of the ICD regarding structure and 
format of content models. The seven major categories of chronic pain were identified after 
considerable research and discussion. They represent a compromise between 
comprehensiveness and practical applicability of the classification system. Several clinically 
important conditions that were neglected in former ICD revisions will now be mentioned, e.g. 
chronic cancer pain or chronic neuropathic pain. Etiological factors, pain intensity and 
disability related to pain will be reflected. With the introduction of chronic primary pain as a 
new diagnostic entity, the classification recognizes conditions that affect a broad group of 
pain patients and would be neglected in etiologically defined categories. We hope that this 
classification strengthens the representation of chronic pain conditions in clinical practice and 
research and welcome comments to improve it further.  
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Figure legend:  
Fig. 1: Organizational chart of Task Force, IASP and WHO interactions. The IASP Task 
Force was created by the IASP council and its scope defined in direct consultation of the 
chairs (RDT and WR) with WHO representatives in 2012. The Task Force reports to the IASP 
Council on an annual basis. 
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Appendix: Structure of the Chapter on Chronic Pain 
 
 
Chronic Pain 
(Persistent or recurrent pain lasting longer than 3 months) 
 
 
1 Chronic primary pain 
1.1 Widespread chronic primary pain (including fibromyalgia syndrome) 
1.2 Localized chronic primary pain (including non-specific back pain, chronic pelvic 
pain) 
1.x Other chronic primary pain 
1.z Chronic primary pain NOS 
2 Chronic cancer pain  
2.1 Chronic pain due to cancer and metastases 
2.2 Chronic Chemotherapy-induced pain 
    [Primary parent: Chronic neuropathic pain] 
2.3 Chronic Pain due to cancer surgery 
    [Primary parent: Chronic postsurgical and posttraumatic pain] 
2.4 Chronic Pain due to radiotherapy 
2.x Other chronic pain related to cancer 
2.z Chronic cancer pain NOS 
3 Chronic postsurgical and posttraumatic pain  
3.1 Chronic postsurgical pain 
3.2 Chronic posttraumatic pain 
3.x Other chronic postsurgical and posttraumatic pain 
3.z Chronic postsurgical and posttraumatic pain NOS 
4 Chronic neuropathic pain  
4.1 Peripheral neuropathic pain 
4.2 Central neuropathic pain 
4.x Other neuropathic pain 
4.z Neuropathic pain NOS 
5 Chronic headache and orofacial pain  
5.1 Chronic primary headaches* 
5.2 Chronic secondary headaches* 
5.3 Chronic orofacial pains** 
5.z Headache and orofacial pain NOS* 
6 Chronic visceral pain 
6.1 Chronic visceral pain from persistent inflammation 
6.2 Chronic visceral pain from vascular mechanisms 
6.3 Chronic visceral pain from obstruction/distension 
6.4 Chronic visceral pain from traction/compression 
6.5 Chronic visceral pain from combined mechanisms 
6.6 Chronic visceral pain referred from other locations 
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6.7 Chronic visceral pain from cancer  
    [Primary parent: Chronic cancer pain] 
6.8 Functional or unexplained chronic visceral pain  
    [Primary parent: Chronic primary pain] 
6.x Other chronic visceral pain 
6.z Chronic visceral pain NOS 
 
7 Chronic musculoskeletal pain 
7.1 Chronic musculoskeletal pain from persistent inflammation 
7.2 Chronic musculoskeletal pain from structural osteo-articular changes 
7.3 Chronic musculoskeletal pain due to disease of the nervous system 
    [All neuropathic pain will be classified under 4. Chronic neuropathic pain.  
    Here other chronic musculoskeletal pain originating from diseases of the 
    nervous system, e.g. spastic pain] 
7.4 Chronic non-specific musculoskeletal pain 
  [Primary parent: Chronic primary pain] 
7.x Other chronic musculoskeletal pain syndromes 
7.z Chronic musculoskeletal pain NOS 
 
_____________ 
Notes: 
* These disorders have in part been renumbered as compared to the ICHD-3 
** #5.3 is not part of the ICHD-3 
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Table 1. Glossary of ICD-11 terms 
WHO Term Explanation 
(Diagnostic) entity The unit of classification, e.g. individual diagnoses and diagnostic 
chapters. 
Content model A structured framework that contains all information required to 
describe an entity within the ICD. A content model contains 
information on an entity's name, its definition, the affected body 
system or structure, the disease course, its etiology, treatment and 
limitations in physical, emotional or social functioning associated with 
the entity. 
Parent/child Entities are arranged in a hierarchical order, with a ‘parent’ entity at 
the top, e.g., ‘chronic pain’, and child entities subsumed underneath, 
e.g., ‘chronic neuropathic pain’. Child entities can be parent to the next 
level, e.g., ‘chronic neuropathic pain’ is a parent relative to ‘chronic 
peripheral neuropathic pain’. 
Multiple Parenting Entities can have more than one parent. An entity such as ‘chronic 
chemotherapy-induced pain’ has, e.g., ‘chronic cancer pain’ and 
‘chronic neuropathic pain’ as parents. One of them is designated as the 
‘primary’ parent, but the entity can be found under either heading. 
Multiple parenting thus allows one entity to be included in two or more 
diagnostic categories.  
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 Diseases or clinical conditions 
associated with chronic pain 
R.-D. Treede (DE) and W. Rief (DE) 
assisted by A. Barke (DE)
Primary Pain
J. Vlaeyen (BE)
M. Nicholas (AU)
Postsurgical and
Posttraumatic Pain
S. Schug (AU)
P. Lavand‘homme (BE)
Cancer Pain
M.I. Bennett (UK)
S. Kaasa (NO)
Musculoskeletal Pain
S. Perrot (FR)
M. Cohen (AU)
Visceral Pain
M.A. Giamberardino (IT)
Q. Aziz (UK)
Neuropathic Pain
J. Scholz (US)
N.B. Finnerup (DK)
Headache
S. Evers (DE)
S.-J. Wang (TW)
Orofacial Pain
P. Svensson (DK)
R. Benoliel (US)
Primary Care Applicability
B. Smith (UK)
General Advice
M.B. First (US), ICD 
E. Kosek (SE), IASP Terminology group
IASP CouncilWHO
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